A'sha Brown, MD
Retina Specialist · Media, PANPI 1255674719
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $825 of the $1,246 with a category attached, or 66.2%. 20 manufacturers reported payments, led by Notal Vision, Inc. at 33.8% of the total. Reporting peaked in 2021 at $473 and has fallen 80.4% since, to $93 in 2025. That places this record below the midpoint for retina specialist clinicians in PA, where the typical reported total is $2,388.
Across 42 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Notal Vision, Inc.$421
- Regeneron Healthcare Solutions, Inc.$187
- AbbVie$113
- Bausch & Lomb Americas Inc.$77
- Genentech USA, Inc.$72
- Novartis$45
- plus $331 from 14 others
What the payments were for
- Speaking & faculty fees$42134%
- Food & beverage$82566%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,246 in reported general payments places this provider in the 35th percentile of 43 retina specialist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 37 | $21,081 |
| Travoprost | 13 | $2,754 |
| Prednisolone Acetate | 21 | $2,063 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 62 | $1,985 |
| TafluprostTafluprost/Pf | 12 | $1,844 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,330 |
| Latanoprost | 83 | $836 |
| Timolol Maleate | 16 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $113 | $21,08137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 43 retina specialist providers in Pennsylvania.
Other retina specialist in Media
- Joshua GreenePhiladelphia$394K
- Jay ChhablaniPittsburgh$70K
- Sachin PatelPottsville$17K
- Brian VanderbeekPhiladelphia$14K
- Thucanh MultererFogelsville$9K
- Christopher BairHermitage$9K
- Albert MaguirePhiladelphia$9K
- Hugo LinaresPhiladelphia$7K
- Moiz CarimWyomissing$6K
- Salman PorbandarwallaLancaster$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.